Von Hippel Lindau (VHL) (NM_000551) Human Recombinant Protein

CAT#: TP760451

Purified recombinant protein of Human von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, full length, with N-terminal HIS tag, expressed in E.Coli, 50ug

Product Images

Specifications

Product Data

• Species: Human
• Expression Host: E. coli
• Expression cDNA Clone or AA Sequence:
  Protein Sequence

  A DNA sequence encoding human full-length VHL
• Tag: N-His
• Predicted MW: 24 kDa
• Concentration: >50 ug/mL as determined by microplate BCA method
• Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining
• Buffer: 25mM Tris, pH8.0, 150 mM NaCl, 10% glycerol, 1 % Sarkosyl.
• Storage: Store at -80°C.
• Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.

Reference Data

• RefSeq: NP_000542
• Locus ID: 7428
• UniProt ID: P40337, A0A024R2F2
• Cytogenetics: 3p25.3
• Refseq Size: 2968
• Refseq ORF: 639
• Synonyms: HRCA1; pVHL; RCA1; VHL1
• Summary: 'Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008]'
• Protein Families: Druggable Genome, Transcription Factors
• Protein Pathways: Pathways in cancer, Renal cell carcinoma, Ubiquitin mediated proteolysis